Results 171 to 180 of about 212,106 (307)

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy. [PDF]

Drugs
Cooperrider JH, Derman BA.
europepmc   +1 more source

CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry [PDF]

, 2011
Françoise Solly, Fanny Angelot, Richard Garand, Christophe Ferrand, Estelle Seillès, Françoise Schillinger, Agnès Decobecq, Maryse Billot, Fabrice Larosa, Emmanuel Plouvier, Éric Deconinck, Faézeh Legrand, Philippe Saas, Pierre‐Simon Rohrlich, Francine Garnache‐Ottou   +14 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches. [PDF]

Int J Mol Sci
Murray NP, Aedo S.
europepmc   +1 more source

Tumor <i>In Situ</i> Fluid Was Used to Characterize Glioma in Real-Time to Monitor Minimal Residual Disease and Tumor DNA Relapse

, 2021
Jinliang Yu, Zhiyuan Sheng, Yushuai Gao, Zhaoyue Yan, Chaojie Bu, Jianjun Gu, Yage Bu, Kaiyuan Deng, Shuang Wu, Sensen Xu, Sen Hu, Nianxuan Li, Zhongcan Chen, Ajmal Zemmar, Fitri Sepviyanti Sumardi, Juha Hernesniemi, Lingfei Kong, Gang Liu, Meiyun Wang, Tianxiao Li, Xingyao Bu   +20 more
openalex   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis. [PDF]

Ann Med
Li X, Chen M, Liu J, Gu J, Huang B, Kuang L, Li J.   +6 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Detection and Monitoring of Breast Cancer Local Recurrence Via Circulating Tumor DNA Minimal Residual Disease Assay. [PDF]

JCO Precis Oncol
Prasath V, Jhawar SR, To B, Mestres-Villanueva MA, Schneider BP, Reátegui E, Stover DG.   +6 more
europepmc   +1 more source